10 Chemed Corp. Analyst Ratings, Earnings, Dividends and Insider Trades | $CHE | NYSE:CHE | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Chemed Corp. Company Profile (NYSE:CHE) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Chemed Corp. (NYSE:CHE) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)Consensus Rating:Buy (Score: 2.50)Consensus Price Target: $76.30 11.28% downside) Analysts' Ratings History for Chemed Corp. (NYSE:CHE) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/20/2014ZacksUpgradeNeutral -> Outperform$85.90View 10/30/2013OppenheimerLower Price TargetOutperform$82.00 -> $80.00View 10/30/2013Deutsche BankReiterated RatingHold$64.00 -> $63.00View 9/10/2013Deutsche BankLower Price TargetHold$70.00 -> $63.00View 7/22/2013OppenheimerLower Price Target$85.00 -> $82.00View 7/19/2013ZacksUpgradeUnderperform -> Neutral$76.00View 7/19/2013CL KingDowngradeBuy -> NeutralView 6/20/2013ZacksDowngradeNeutral -> Underperform$71.70View 6/11/2013OppenheimerLower Price Target$91.00 -> $85.00View 4/18/2013OppenheimerReiterated RatingBuy$91.00View 2/20/2013OppenheimerBoost Price TargetOutperform$91.00View 10/31/2012Deutsche BankBoost Price TargetHold$67.00 -> $70.00View 10/3/2012OppenheimerBoost Price TargetOutperform -> Outperform$75.00 -> $80.00View (Data available from 3/10/2012 forward) Earnings History for Chemed Corp. (NYSE:CHE)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare10/29/2013Q313$1.34$1.36$355.40 million$340.90 millionViewListenView 7/18/2013Q2 2013$1.33$1.44$368.06 million$357.00 millionViewListenView 4/18/2013Q1 2013$1.29$1.38$365.08 million$367.00 millionViewListenView 2/18/2013Q4 2012$1.15$1.57$355.31 million$369.00 millionViewListenView 10/29/2012Q312$1.35$1.28$360.50 million$354.00 millionViewN/AView 7/25/2012$1.26$1.26ViewN/AView 4/19/2012$1.25$1.21ViewN/AView 2/14/2012$1.48$1.45ViewN/AView 10/25/2011$1.15$1.20ViewN/AView 4/26/2011$0.98$1.07ViewN/AView 2/15/2011$1.05$0.98ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Chemed Corp. (NYSE:CHE)AnnouncedPeriodAmountEx-Dividend DateRecord DatePayable DateShare2/21/2014quarterly$0.202/27/20143/3/20143/24/2014 11/8/2013quarterly$0.2011/14/201311/18/201312/9/2013 8/2/2013quarterly$0.208/8/20138/12/20139/3/2013 5/20/2013quarterly$0.185/28/20135/30/20136/19/2013 2/20/2013quarterly$0.182/28/20133/4/20133/22/2013 (Data available from 1/1/2013 forward) Insider Trading History for Chemed Corp. (NYSE:CHE)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare3/3/2014Kevin McnamaraCEOSell4,000$84.47$337,880.00View 2/28/2014Arthur Tucker, Jr.VPSell9,000$85.01$765,090.00View 2/25/2014Arthur Tucker, Jr.VPSell8,461$83.80$709,031.80View 2/20/2014Spencer LeeEVPSell2,000$82.51$165,020.00View 2/19/2014Kevin McnamaraCEOSell4,000$82.18$328,720.00View (Data available from 1/1/2013 forward) About Chemed Corp. Chemed Corporation (Chemed) purchases, operates and divests subsidiaries engaged in diverse business activities. During the year ended December 31, 2012, Chemed operated in two segments: the Vitas segment (Vitas) and the Roto-Rooter segment (Roto-Rooter). Vitas Healthcare Corporation focuses on hospice care, which helps make terminally ill patients' final days as comfortable as possible. Through its team of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter provides plumbing and drain cleaning services to both residential and commercial customers. Its VITAS Healthcare Corporation (VITAS) subsidiary has acquired the operating assets of Houston-based Solari Hospice Care, effective April 1, 2013. Headlines: (2/19) Chemed Corp. (CHE) in Focus: Stock Moves 10.5% Higher (2/26) Chemed Corp. (CHE) Surges: Why It Still Has Room to Run? (2/26) Chemed Corp. (CHE) Ex-Dividend Date Scheduled for February 27, 2014 (2/26) Chemed Corp. (CHE) Surges: Why It Still Has Room to Run? - Tale of the Tape (2/19) Chemed Corp. (CHE) in Focus: Stock Moves 10.5% Higher - Tale of the Tape (2/17) Chemed Q4 Profit Down - Update (2/17) Chemed Q4 Profit Down - Quick Facts (2/24) Investors are betting against Chemed (CHE), Should You? Industry, Sector and Symbol: Sector: Healthcare Industry: Health Care Providers & Services Sub-Industry: Health Care Services Exchange: NYSE Symbol: CHE CUSIP: 16359R10 Key Metrics: Previous Close: $84.8750 Day Moving Average: $80.2965200 Day Moving Average: $74.697 P/E Ratio: 20.40P/E Growth: 1.65Market Cap: $1.525BCurrent Quarter EPS Consensus Estimate: $5.89 EPS Additional Links: View CHE on Google FinanceView CHE on Yahoo FinanceView CHE's Company Profile on ReutersSearch for Chemed Corp. on Google Chemed Corp. (NYSE:CHE) Chart for Monday, March, 10, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.